Theravance, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule medicines primarily for therapeutic areas of respiratory diseases, bacterial infections, and central nervous system (CNS)/pain. The company offers VIBATIV, a bactericidal injectable antibiotic for the treatment of Gram-positive infections. Its principal development programs with GlaxoSmithKline plc include the RELOVAIR that has completed Phase 3 clinical studies for the treatment of patients with chronic obstructive pulmonary disease (COPD) or asthma; the LAMA/LABA combination, a Phase 3 program for patients with COPD; and the Bifunctional Muscarinic Antagonist-Beta2 Agonist (MABA) program that has completed Phase 2b study for the treatment of COPD. The company’s principal development programs also comprise and the Peripheral Mu-Opioid Receptor Antagonist (PµMA) program for the TD-1211 mu-opioid receptor designed to alleviate gastrointestinal side effects of opioid therapy without affecting analgesia. In addition, it develops TD-4208 that has completed Phase 2a single-dose COPD study; TD-1792, an antibiotic under clinical-stage for the treatment of serious infections caused by Gram-positive bacteria; MARIN program with compound TD-9855 under Phase 2 study for the treatment of attention-deficit/hyperactivity disorder; TD-5108, which has completed Phase 1 study for the treatment of Alzheimer’s disease, and completed Phase 2 proof-of-concept study for the treatment of chronic idiopathic constipation(CIC); and TD-8954 that has completed single- and multiple-ascending dose Phase 1 studies for treatment of CIC. The company was formerly known as Advanced Medicine, Inc. and changed its name to Theravance, Inc. in April 2002. Theravance, Inc. was founded in 1996 and is headquartered in South San Francisco, California.